CSF2 and juvenile myelomonocytic leukemia: This is consistent with the lack of activating GM-CSF mutation in JMML [7–9] and suggests that a therapeutic strategy antagonizing GM-CSF [13] might efficiently limit JMML proliferation but probably not eradicate the disease.